GMSJ

GMSJ (Guanmian Shujie Oral Liquid) is an investigational Traditional Chinese Medicine (TCM) developed by Yangtze River Pharmaceutical Group (Yangzijiang Pharmaceutical Group) for the treatment of respiratory viral infections, including influenza and COVID-19. Classified as a Class 1.1 innovative TCM in China, the formulation is specifically designed to address the "wind-heat affecting the lungs" syndrome, a common TCM classification for symptoms such as fever, cough, and sore throat. GMSJ is intended to provide a multi-target therapeutic effect, likely involving broad antiviral, anti-inflammatory, and immunomodulatory activities. Clinical development has progressed to Phase II trials for influenza and Phase II/III trials for mild-to-moderate COVID-19, focusing on its potential to accelerate symptom resolution and reduce viral load.

Other names

Guanmian Shujie Oral LiquidGuanmian Shujie